China Isotope & Radiation Corporation (HKG:1763)

Market Cap	5.31B
Revenue (ttm)	8.06B
Net Income (ttm)	432.74M
Shares Out	319.87M
EPS (ttm)	1.35
PE Ratio	12.27
Forward PE	n/a
Dividend	0.42 (2.54%)
Ex-Dividend Date	Jun 5, 2025

Volume	407,200
Average Volume	427,390
Open	16.52
Previous Close	16.42
Day's Range	16.36 - 16.92
52-Week Range	9.30 - 18.00
Beta	0.78
RSI	67.50
Earnings Date	Aug 29, 2025

About Revance Therapeutics

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmace...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 3,367
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1763

Financial Performance

In 2024, China Isotope & Radiation's revenue was 7.57 billion, an increase of 14.16% compared to the previous year's 6.63 billion. Earnings were 406.65 million, an increase of 9.62%.